Settlement Reached#
Apimeds Pharmaceuticals US, Inc. has announced a settlement with Inscobee Inc. and Apimeds Inc., resolving disputes stemming from its merger with MindWave Innovations Inc. that occurred on December 1, 2025. This settlement confirms the legitimacy of the Stockholder Support and Lock-Up Agreement, which is crucial for ensuring that stockholder votes are valid.
Stock Trading Resumes#
Following the settlement, Apimeds' common stock is set to resume trading on the NYSE American today, pending approval from the exchange. This marks a significant step forward for the company as it navigates through its recent challenges.
Key Developments#
Under the terms of the settlement, Lōkahi Therapeutics will gain rights to the Apitox program, which includes important intellectual property and development data. Lōkahi is required to pay $4 million to Apimeds within five business days of the settlement's effective date. Additionally, Apimeds will assign a $2.2 million credit facility to Lōkahi to aid in the development of the Apitox program.
Corporate Changes#
In a related development, Apimeds has appointed Sungjoon Chae as co-chief executive officer, effective May 4. This appointment follows a nomination by a stockholder and does not involve any undisclosed arrangements or family ties. Furthermore, MindWave Innovations has taken legal action against Inscobee Inc. for attempting to replace its board of directors, which MindWave claims is invalid. These developments illustrate the ongoing shifts and challenges within Apimeds Pharmaceuticals.